En Español | Plain Text Version | Skip Navigation

You are here:  Home > Funding & Research > Funding News > March 2002

Funding News - Applications for Neurodegenerative Disease Assays Requested

Skip secondary menu

The National Institute of Neurological Disorders and Stroke (NINDS) requests applications for research to develop neurodegenerative disease assays for high throughput drug screening and chemical genetics.*

The purpose of this request for applications (RFA) is to encourage the use of high throughput drug screening and chemical genetics in neurodegeneration research by funding the development of assays that may be adapted for high throughput approaches.

Assays proposed for this RFA should represent mechanisms associated with neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, and triplet repeat disorders such as Huntington's disease. Appropriate assays include: toxicity of disease-causing proteins in neuronal cell lines or primary neuronal cultures; toxicity of disease-causing proteins in yeast or other model organisms; modulation of expression of disease-causing or neuroprotective genes, including effects on transcription, translation, or splicing; cell-based assays of activity, processing, or turnover of disease-causing or neuroprotective proteins; and biochemical assays of activity of disease-causing or neuroprotective proteins.

APPLICATION RECEIPT DATE: March 26, 2002.

For more information, potential applicants should contact Neurodegeneration Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2204, Bethesda, MD 20892; telephone: 301-496-5680; fax: 301-480-1080; e-mail: funding@ninds.nih.gov.

*For a more detailed description of this RFA, please visit the NIH web site at: http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-02-012.html.

This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site.  For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.